Stem Cell-Derived CAR-NKT Cells Engineered to Destroy Kidney Cancer Tumors

Renal cell carcinoma is the most common kidney malignancy in adults, and most patients are diagnosed at an advanced or metastatic stage where conventional therapies offer limited benefit. CD70, a TNF superfamily ligand, is highly and consistently overexpressed on RCC tumor cells while showing minimal expression on normal tissues, making it an attractive immunotherapy target. Current CD70-directed strategies include monoclonal antibodies and CAR-T cell approaches, but both face manufacturing bottlenecks or donor-variability issues. This protocol paper from Li and Yang at UCLA addresses those challenges by establishing a reproducible, clinically translatable workflow for generating allogeneic CAR-NKT cells from cord blood HSPCs.

The manufacturing workflow begins with commercially obtained cord blood CD34+ HSPCs from HemaCare. These cells are first transduced with a lentiviral vector encoding three key elements: an iNKT TCR (Vα24-Jα18/Vβ11) to enforce NKT cell identity, a second-generation CD70-directed CAR construct (anti-CD70 scFv fused to 4-1BB and CD3ζ signaling domains), and a membrane-bound IL-15 transgene to promote autocrine survival signaling. Following transduction, HSPCs undergo a multi-phase ex vivo differentiation protocol employing sequential cytokine cocktails — including SCF, TPO, Flt3-L, IL-3, IL-7, IL-15, IL-21, and alpha-galactosylceramide stimulation — that progressively guide cells through hematopoietic progenitor expansion, T/NKT lineage commitment, and final NKT maturation. The entire differentiation process is conducted in clinically guided conditions intended to facilitate future GMP translation.

Tumor cell lines used for functional validation include 786-O and ACHN human RCC lines, which were engineered with a dual firefly luciferase/GFP (FG) reporter system via lentiviral transduction and FACS-sorted to 100% purity. This dual-reporter system allows simultaneous quantification of tumor cell killing by luminescence bioluminescence assay and visual confirmation by flow cytometry or fluorescence microscopy — enabling precise, quantitative assessment of cytotoxicity across a range of effector-to-target ratios. The protocol also includes ELISA-based measurement of key cytokines secreted by AlloCAR70-NKT cells upon tumor contact, including IFN-γ, TNF-α, IL-2, IL-4, and IL-15, providing a comprehensive functional readout of the immune effector response.

Phenotypic characterization of the final cell product relies on a multi-parameter flow cytometry panel that assesses expression of TCR Vα24-Jα18, Vβ11, CD3, CD4, CD5, CD7, CD8, CD34, CD45, and CD70. The inclusion of CD70 in the phenotyping panel is particularly important because CD70-CAR-expressing NKT cells could theoretically engage in fratricidal killing if residual CD70 surface expression occurs on the effector cells themselves — a potential manufacturing pitfall the protocol explicitly flags and monitors. The IL-15 transgene is incorporated precisely to address the short in vivo persistence that has historically limited NKT cell therapy.

The protocol is explicitly modular: the HSPC transduction step can accommodate additional genetic edits, such as CRISPR-mediated checkpoint gene disruption (e.g., PD-1, TIGIT) or knock-in of additional cytokine armoring cassettes, before differentiation begins. This flexibility positions the platform as a foundation for next-generation, multi-edited CAR-NKT products. The authors note that AlloCAR70-NKT cells show potent cytotoxic activity against RCC lines with varying CD70 expression densities — modeling low- and high-antigen scenarios — and produce robust cytokine signatures consistent with activated effector NKT cell biology. Future work will need to advance these findings into in vivo xenograft models and ultimately clinical trials.